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ABSTRACT: Background: Studies on early-onset pre-
sentations of progressive supranuclear palsy (PSP) have
been limited to those where a rare monogenic cause has
been identified. Here, we have defined early-onset PSP
(EOPSP) and investigated its genetic and clinico-
pathological profile in comparison with late-onset PSP
(LOPSP) and Parkinson’s disease (PD).
Methods: We included subjects from the Queen Square
Brain Bank, PROSPECT-UK study, and Tracking
Parkinson’s study. Group comparisons of data were
made using Welch’s t-test and Kruskal-Wallis analysis of
variance. EOPSP was defined as the youngest decile of
motor age at onset (≤55 years) in the Queen Square
Brain Bank PSP case series.
Results: We identified 33 EOPSP, 328 LOPSP, and 2000
PD subjects. The early clinical features of EOPSP usually
involve limb parkinsonism and gait freezing, with 50% of
cases initially misdiagnosed as having PD. We found that an
initial clinical diagnosis of EOPSP had lower diagnostic
sensitivity (33%) and positive predictive value (38%) in com-
parison with LOPSP (80% and 76%) using a postmortem
diagnosis of PSP as the gold standard. 3/33 (9%) of the
EOPSP group had an underlying monogenic cause. Using a
PSP genetic risk score (GRS), we showed that the genetic
risk burden in the EOPSP (mean z-score, 0.59) and LOPSP
(mean z-score, 0.48) groups was significantly higher
(P < 0.05) when compared with the PD group (mean z-
score, −0.08).
Conclusions: The initial clinical profile of EOPSP is often
PD-like. At the group level, a PSP GRS was able to dif-
ferentiate EOPSP from PD, and this may be helpful in
future diagnostic algorithms. © 2019 The Authors. Move-
ment Disorders published by Wiley Periodicals, Inc. on
behalf of International Parkinson and Movement Disorder
Society.
Key Words: clinical neurology; genetics; Parkinson’s
disease/parkinsonism; progressive supranuclear palsy
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Progressive supranuclear palsy (PSP) is a neurodegener-
ative disease and common cause of atypical parkinson-
ism, with an estimated prevalence of 5 to 7 per 100,000.1
The neuropathology of PSP, the gold standard for diag-
nosis, is centred on the structural microtubule-associated
protein tau, encoded by theMAPT gene.2
A comprehensive, case-control genome-wide associa-
tion study has shown that loci at MAPT (H1 haplotype
and H1c subhaplotype), MOBP, STX6, and EIF2AK3
are associated with PSP.3
The clinical heterogeneity of PSP has been highlighted
by the description of Richardson’s syndrome (RS)4,5 and
other syndromes with identical pathology including
PSP-parkinsonism (PSP-P) and PSP-pure akinesia with
gait freezing (PSP-PGF),6,7 which are included in recent
Movement Disorder Society (MDS) diagnostic criteria.8
This heterogeneity is associated with common variation
at the TRIM11 locus9 and variability in the regional dis-
tribution and density of pathogenic tau accumulation.10
Studies involving younger patients with PSP have
focused on familial cases with an identified single gene
mutation despite the fact that PSP is considered to be a
sporadic disease.11 Studies of autosomal-dominant famil-
ial PSP phenotypes with variable disease durations and
PSP-type tau pathology at postmortem examination have
identified MAPT and LRRK2 mutations.11 Of note,
monogenic PSP mimics in younger patients include Perry
syndrome (DCTN1 mutations) and Niemann-Pick type
C (NPC1/NPC2)mutations.11,12
In this study, we define early-onset PSP (EOPSP),
clarify its differential diagnosis, describe its clinico-
pathological profile, and identify potential determinants
of early-onset disease.
Methods
Patient Consent
All patients gave written informed consent for the use
of their medical records and brain tissue/blood samples
for research purposes, including the analysis of DNA.
All subjects, regardless of their pathological diagnosis,
who had an antemortem clinical diagnosis of PSP at any
point in their disease course were identified from the
Queen Square Brain Bank (QSBB), with the year of death
ranging from 2000 to 2018. The brain donor program
was approved by a London multicenter research ethics
committee, and tissue is stored for research under a
license from the Human Tissue Authority, No. 12198. To
enable the calculation of diagnostic sensitivity and positive
predictive value (PPV), we later included patients with a
postmortem diagnosis of PSP where PSP was not the ini-
tial or final clinical diagnosis.
Progressive Supranuclear Palsy-Corticobasal Syn-
drome-Multiple System Atrophy-UK (PROSPECT-UK)
is a U.K.-wide longitudinal study of patients with
atypical parkinsonian syndromes, including PSP (Queen
Square Research Ethics Committee 14/LO/1575). Sub-
jects with a baseline clinical diagnosis of PSP from the
PROSPECT-UK study were identified, with the year of
recruitment ranging from 2015 to 2018.13
Tracking Parkinson’s is a U.K.-wide longitudinal study of
Parkinson’s disease (PD) across 72 sites, with multicenter
ethics committee and local research and development
department approvals. Subjects with a baseline clinical diag-
nosis of PD were identified, with the year of recruitment
ranging from 2012 to 2014.14 PD cases were diagnosed
consistent with QSBB clinical diagnostic criteria.15
Defining EOPSP
EOPSP was defined in patients with a clinical diagno-
sis of PSP, consistent with MDS clinical diagnostic
criteria,8 and a motor symptom onset ≤55 years of age.
This threshold was used as it represented the youngest
decile of age at motor symptom onset in the QSBB series
of pathologically diagnosed PSP cases. Late-onset PSP
(LOPSP) was defined as cases with a clinical diagnosis of
PSP and a motor symptom onset >55 years of age.
Clinical Data Collection and Phenotyping
The following clinical features were recorded for each case:
sex, ethnicity, family history of dementia and/or parkinsonism
in first-degree relatives, age at motor symptom onset, initial
clinical diagnosis and PSP phenotype, final/current clinical
diagnosis and PSP phenotype, diagnostic latency (from motor
symptom onset to correct diagnosis), and disease duration
(from motor symptom onset to death) in deceased cases. Of
note, the initial clinical diagnosis/phenotype was defined as
the clinical diagnosis/MDS criteria PSP phenotype given to
patients in the first 3 years after their motor symptom onset.
Final/current clinical diagnosis/phenotype was defined as the
clinical diagnosis/MDS criteria PSP phenotype given to
patients at least 2 years after the date of their initial clinical
diagnosis/phenotype. Although we emphasize the age at
motor symptom onset to define EOPSP/LOPSP, we screened
each case for the onset and burden of cognitive symptoms rel-
ative to motor symptom onset to identify patients with frontal
presentations of PSP.
In conjunction with the phenotyping methods described
above, the presence or absence of MDS PSP criteria clinical
features8 in the initial and final/current disease stages were
used to produce radar charts to further highlight the pheno-
typic differences between EOPSP, LOPSP, and PD.
PROSPECT-UK subjects had serial PSP rating scale
(PSPRS) scores recorded, and both PROSPECT-UK and
Tracking Parkinson’s subjects had serial MDS-UPDRS
part III scores recorded to assess the rates of clinical disease
progression.
To compare the rates of encephalitis and head injury
between the EOPSP and LOPSP cases, we collected data
on the presence or absence of a documented past
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medical history of encephalitis in case notes (QSBB
cases only) and the presence or absence of any mode of
head injury resulting in loss of consciousness prior to
the onset of PSP motor symptoms, identified from the
Retrospective Screening of Traumatic Brain Injury
(RESTBI) questionnaire (PROSPECT-UK cases only).
Neuropathological Diagnosis
The neuropathological examinations of EOPSP and
LOPSP cases in this study were carried out at QSBB by
J.L.H. and T.R. The pathological diagnoses of these
cases were used to calculate the diagnostic sensitivity
and PPV of EOPSP and LOPSP using a pathological
diagnosis of PSP as the gold standard. Neuropathologi-
cal data from Tracking Parkinson’s PD cases was not
available for analysis.
Genotyping
PSP and PD cases had DNA extracted from either brain
tissue or blood. We then genotyped DNA samples using
the Illumina (San Diego, CA) NeuroChip16 for all QSBB
and PROSPECT-UK PSP cases, and the Illumina Human
Core Exome array14 for all Tracking Parkinson’s PD
cases. Importantly, none of the PSP cases in this study
had been included in the original PSP case-control
genome-wide association study.3 Standard genotype data
quality control steps were carried out.17 All cases were
screened for the known pathogenic MAPT, LRRK2,
PRKN, PINK1, SNCA, GRN, and DCTN1 mutations,
which are directly genotyped on both the Illumina
NeuroChip and Illumina Human Core Exome Array
(detailed list of pathogenic variants can be found in the
supplementary data of Blauwendraat et al.16). Standard
quality control steps for single nucleotide polymorphism
imputation were carried out.17 MAPT H1/H1 frequency
(determined by rs1800547 genotype), TRIM11 minor
allele frequency (determined by rs564309 genotype), and
APOE ε4 allele frequency (determined by rs429358 and
rs7412 genotypes) were extracted for all cases. In addi-
tion, one biochemically proven case of Niemann-Pick
type C disease had targeted sequencing to identify patho-
genic mutations in theNPC1 andNPC2 genes.
Statistical Analyses
All statistical analyses were carried out using Stata ver-
sion 15 (StataCorp. 2017. Stata Statistical Software:
Release 15. College Station, TX: StataCorp LLC) and
Plink version 1.9 (Harvard University, Cambridge, MA).
Figures were generated using R version 3.3.2
(R Foundation for Statistical Computing, Vienna, Aus-
tria). Statistical significance was defined as P < 0.05.
We studied the pathological diagnoses and/or genetic
mutation status of the EOPSP, LOPSP, and PD cases.
Cases with alternative pathological and/or genetic diag-
noses were excluded from subsequent analyses of
clinical and genetic data. Group comparisons of clinical
features were made using Welch’s t-test.
Clinically diagnosed PSP and PD cases with an alter-
native current clinical diagnosis were excluded from
our genetic analyses. A PSP genetic risk score (GRS),
based on weighted odds ratios for all risk loci (MAPT
H1 haplotype and H1c subhaplotype, MOBP, STX6,
and EIF2AK3) identified in the original PSP case-
control genome-wide association study,3 was calculated
for all white PSP and PD cases (confirmed by principal
component analysis). Group comparisons of PSP GRS
z-scores were made using Kruskal-Wallis analysis of
variance.
We used t-testing to look for clinical and genetic dif-
ferences between QSBB and PROSPECT-UK cases
within our EOPSP and LOPSP groups.
We collected the following data from QSBB cases to
compare the diagnostic sensitivity and PPV of initial and
final clinical diagnoses of EOPSP and LOPSP in our
cohort: (1) the primary pathological diagnosis of all cases
with initial and/or final clinical diagnoses of
EOPSP/LOPSP; (2) the initial and final clinical diagnoses
of all cases with a primary pathological diagnosis of PSP,
which includes cases that never had an antemortem diag-
nosis of PSP.
Variable Age at Onset to Define EOPSP
Alongside our arbitrary age at onset cut-off point
(youngest 10% of QSBB PSP series = ≤55 years) to
define EOPSP, we assessed the impact of changing the
age at onset cut-off point on the clinical profile, PSP
GRS z-score, and diagnostic sensitivity/PPV of EOPSP
in comparison with LOPSP. Specifically, the alternative
age at onset cut-off points studied were as follows:
(1) youngest 5% of QSBB PSP series = ≤52 years;
(2) youngest 15% of QSBB PSP series = ≤59 years;
(3) youngest 20% of QSBB PSP series = ≤62 years;
(4) youngest 25% of QSBB PSP series = ≤64 years.
The definition of LOPSP varied with each alternative
age at onset cut-off point accordingly.
Data Availability
The raw data used for analyses in this study will be
considered for sharing in anonymized format by request
of a qualified investigator to the corresponding authors
for purposes of replicating the procedures and results.
Results
We identified 361 subjects with a clinical diagnosis of
PSP at any point in their disease course from the QSBB
and PROSPECT-UK study with detailed clinical data
available throughout the entire disease course. Of the PSP
cases, 33/361 (9%) fulfilled criteria for EOPSP. In addi-
tion, 2000 PD cases from the Tracking Parkinson’s study
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were included. The neuropathological and genetic muta-
tion status of our groups are summarized in Table 1. All
PSP subjects with alternative pathological diagnoses were
excluded from subsequent analyses. In our EOPSP group,
two cases had MAPT mutations that have previously
been reported in subjects with PSP pathology.18,19 One
EOPSP case had previously described pathogenic NPC1
mutations20 and was therefore excluded from subsequent
analyses. A total of 21 PD cases had LRRK2, PRKN,
and SNCA mutations previously reported in subjects
with PD pathology.21
The clinical profiles of our groups are summarized in
Table 2. The initial clinical profile of EOPSP was more
PD-like when compared with LOPSP (Fig. 1). The
final/current clinical profiles of EOPSP and LOPSP both
resembled RS (Fig. 1). Deceased EOPSP cases had a
longer disease duration than deceased LOPSP and PD
cases (Table 2). However, only 5% of the Tracking
Parkinson’s study cohort were deceased at the point of
censoring, so a majority of these deceased PD cases are
likely to be atypical fast progressing cases, with no
neuropathological data available. In comparison with
an age-matched (motor symptom onset ≤55 years)
cohort of PD cases from the Tracking Parkinson’s study
(n = 328, mean age at onset = 48.5 years), our EOPSP
group had a significantly longer mean diagnostic
latency (3.2 vs. 2.5 years; P < 0.05).
None of the QSBB EOPSP or LOPSP cases had a past
medical history of encephalitis. Of the PROSPECT-UK
EOPSP cases, 1/12 (8%) reported experiencing a head
injury that resulted in a loss of consciousness prior to the
onset of PSP motor symptoms compared with 7/183
(4%) of the PROSPECT-UK LOPSP cases. The mean
latency of time from concussive head injury to onset of
PSP motor symptoms was 44.5 years in the EOPSP group
and 38.9 years in the LOPSP group.
A total of 1878 cases had genotyping data available
that passed quality control thresholds to be included in
genetic analyses. Of note, the two EOPSP MAPT muta-
tion cases were excluded from these analyses. The minor
allele frequency of the TRIM11 rs564309 single nucleo-
tide polymorphism was higher in the EOPSP group in
comparison with the LOPSP group, coinciding with a
higher rate of non-RS phenotypes in EOPSP. We found
significantly higher PSP GRS z-scores in the EOPSP and
LOPSP groups when compared with the PD group,
with no significant differences between the EOPSP
and LOPSP groups (Table 3). Summary statistics for
individual PSP risk loci that were included in the PSP
GRS are available online (Supporting Information
Table 1).
A subset of PROSPECT-UK EOPSP (n = 5) and LOPSP
(n = 42) cases, and Tracking Parkinson’s PD (n = 570)
cases, had baseline and 2-year or 3-year PSPRS and/or
MDS-UPDRS part III scores recorded. There were similar
mean baseline clinical rating scale scores between EOPSP
(PSPRS = 34.2, MDS-UPDRS part III = 33.2) and LOPSP
(PSPRS = 33.4, MDS-UPDRS part III = 37.5) groups,
TABLE 1. Neuropathological and genetic mutation status of study cohort
Feature EOPSP LOPSP PD
No. of subjects 33 328 2000
Postmortem cohort with a
pathological diagnosis of PSP,
n/N (% of postmortem cohort)
14/20 (70) 129/158 (82)
Postmortem cohort with alternative
pathological diagnoses, n/N
(% of postmortem cohort)
AD: 2/20 (10)
PD: 2/20 (10)
CBD: 1/20 (5)
MSA: 1/20 (5)
CBD: 10/158 (6)
PD: 5/158 (3)
AD: 4/158 (3)
MSA: 4/158 (3)
ALS: 2/158 (1)
PiD: 2/158 (1)
AGD: 2/158 (1)
Cases with a pathogenic genetic
mutation, n/N (% of whole group)
3/33 (9) 0/328 (0) 21/1566 (1)
Pathogenic genetic mutations
(number of cases)
MAPT IVS10 + 16 (1)
MAPT L284R (1)
NPC1 heterozygous
c.1844G > T p.(Arg615Leu)
and NPC1 heterozygous
c.3182T > C p.(IIe1061Thr)
(1)
None LRRK2 G2019S (17)
LRRK2 R1441C heterozygous (2)
PRKN p.P113Xfs/PRKN exon 5 hemizygous deletion
(compound heterozygous) (1)
SNCA heterozygous duplication of exons 1-6 (1)
EOPSP, early-onset PSP; LOPSP, late-onset PSP; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; AD, Alzheimer’s disease; CBD, corticobasal
degeneration; MSA, multiple system atrophy; ALS, amyotrophic lateral sclerosis; PiD, Pick’s disease; AGD, argyrophilic grain disease; MAPT, microtubule-
associated protein tau; NPC1, Niemann-Pick type C1; LRRK2, leucine-rich repeat kinase 2; PRKN, Parkin; SNCA, alpha synuclein.
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although the mean disease duration at baseline testing in
the EOPSP group was higher in comparison with the
LOPSP group (4.1 years vs. 2.6 years). We found no sig-
nificant differences in the subscale (history, mentation,
bulbar, ocular, limb, and gait) scores of the baseline
PSPRS between the EOPSP and LOPSP groups. The
mean baseline MDS-UPDRS part III score was signifi-
cantly higher in the LOPSP group when compared with
the PD group (37.5 vs. 20.9; P < 0.05). We found that
there was a non-significant trend toward the mean
annualized change in PSPRS being lower in the EOPSP
group when compared with the LOPSP group (+9.9
vs. +12.8). In contrast, the mean annualized change in
MDS-UPDRS part III scores were significantly lower in
the PD group when compared with both EOPSP and
LOPSP groups (+3.3 vs. +19.6 and +14.9; P < 0.05),
with no significant difference between the EOPSP and
LOPSP groups.
Using a pathological diagnosis of PSP as the gold
standard, we reviewed 160 QSBB cases and found that
an initial clinical diagnosis of EOPSP had a lower diag-
nostic sensitivity (33%) and PPV (38%) in comparison
with an initial clinical diagnosis of LOPSP (80% and
76%). In contrast, the diagnostic sensitivity and PPV of
TABLE 2. Clinical profile of study cohort
Feature EOPSP LOPSP PD
No. of subjects 26 299 2000
% male 69 62 65
Ethnicity (% of cases) CEU (92)
Non-CEU (8)
CEU (92)
Non-CEU (8)
CEU (97)
Non-CEU (3)
Family history of dementia and/or parkinsonism, % of cases 27 15 22
Age at motor symptom onset, yr–mean (SD), range 51.0a,b,c
(4.8)
40–55
68.1c
(6.3)
56–88
64.4
(9.7)
23–90
Initial clinical diagnosis (% of cases) PD (50)
PSP (31)
VascP (7)
Dementia (4)
CBS (4)
ET (4)
PSP (80)
PD (10)
CBS (7)
FTD (2)
NPH (1)
PD (100)
Initial PSP phenotype (% of cases) s.o. PSP-P (31)
prob. PSP-RS (27)
poss. PSP-PGF (19)
prob. PSP-P (15)
s.o. PSP-F (4)
s.o. PSP-CBS (4)
prob. PSP-RS (64)
prob. PSP-P (12)
poss. PSP-PGF (8)
s.o. PSP-CBS (7)
s.o. PSP-P (6)
s.o. PSP-F (3)
Final/current clinical diagnosis (% of cases) PSP (96)
CBS (4)
PSP (91)
CBS (5)
MSA (1)
FTD (1)
LBD (1)
APS (1)
PD (98)
SWEDD (0.4)
MSA (0.3)
PSP (0.2)
Otherd (1.1)
Final/current PSP phenotype (% of cases) prob. PSP-RS (84)
prob. PSP-P (8)
prob. PSP-PGF (4)
s.o. PSP-CBS (4)
prob. PSP-RS (84)
s.o. PSP-CBS (5)
prob. PSP-P (4)
poss. PSP-CBS (3)
prob. PSP-PGF (2)
prob. PSP-F (2)
Diagnostic latency, yr–mean (SD) 3.2a,b,c
(1.5)
2.2c
(1.3)
1.8
(2.8)
% of cases deceased 69 56 5
Disease duration in deceased cases, yr–mean (SD), range 10.5a,b,c
(3.9)
4.4–15.2
6.2c
(2.6)
2.4–15.9
6.0
(5.0)
2.3–45.2
Group comparisons made using Welch’s t-test.
aP < 0.05 vs. PD.
bP < 0.05 vs. LOPSP.
cNo significant intra-group difference between Queen Square Brain Bank and PROSPECT-UK cases.
dOther diagnoses consist of essential tremor, corticobasal syndrome, dystonic tremor, functional neurological disorder, multiple sclerosis, and vascular
parkinsonism.
EOPSP, early-onset PSP; LOPSP, late-onset PSP; PD, Parkinson’s disease; CEU, Caucasian residents of European ancestry from Utah; SD, standard deviation;
PSP, progressive supranuclear palsy; VascP, vascular parkinsonism; CBS, corticobasal syndrome; ET, essential tremor; FTD, frontotemporal dementia; NPH, nor-
mal pressure hydrocephalus; s.o., suggestive of; prob., probable; poss., possible; PSP-P, PSP-parkinsonism; PSP-RS, PSP-Richardson’s syndrome; PSP-PGF,
PSP-pure akinesia with gait freezing; PSP-F, PSP-frontal; PSP-CBS, PSP-corticobasal syndrome overlap; LBD, Lewy body dementia; APS, atypical parkinsonian
syndrome; SWEDD, scans without evidence of dopaminergic deficit; MSA, multiple system atrophy.
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a final clinical diagnosis of EOPSP (93% and 76%)
were higher and similar to that of LOPSP (89%
and 84%).
We carried out analyses to investigate the impact of
using alternative age at onset cut-off points to define
EOPSP (Table 4). This revealed that as the age at onset
cut-off point was increased, the EOPSP and LOPSP
groups became more homogeneous in their clinical phe-
notype and PSP GRS z-scores.
Discussion
This is the first study to define EOPSP and describe
its genetic and clinico-pathological profile. Using our
definition of an age at motor symptom onset ≤55 years
of age, we found that up to 10% of PSP cases were
early-onset in nature. A similar frequency of cases has
been observed in young-onset PD (defined as age at
onset <50 years of age22) and young-onset multiple sys-
tem atrophy (defined as age at onset <40 years of
age23).
Our study highlights a number of important points
that are relevant to both clinical and research settings.
First, we show the value of screening patients pre-
senting with an EOPSP syndrome for PSP mimics and
rare genetic mutations known to cause familial PSP
pathology. Of note, higher rates of a family history of
dementia and/or parkinsonism were noted in the
EOPSP group when compared with the LOPSP group,
even when we discount the two identified MAPT muta-
tion EOPSP cases. This observation has been noted in
PSP previously24 and suggests that there may be novel
genetic causes of familial PSP that have yet to be
identified.
The overall diagnostic sensitivity and PPV of an ini-
tial clinical diagnosis of EOPSP was considerably lower
than that of LOPSP. The diagnostic sensitivity and PPV
of a final clinical diagnosis of EOPSP and LOPSP were
predictably higher and similar to values obtained by
Hughes and colleagues.25
In comparison with LOPSP and PD, a clinical diagno-
sis of EOPSP had a longer diagnostic latency; 50% of
our EOPSP cases were initially misdiagnosed as PD, and
this coincided with the initial clinical profile of EOPSP
being dominated by limb parkinsonism and gait freezing.
The most common initial MDS PSP criteria phenotypes
in association with these presentations were “suggestive
of” PSP-P and “possible” PSP-PGF. In these cases,
although abnormal eye movements had yet to occur to
permit “probable” PSP-P/PSP-PGF diagnoses, the pres-
ence of early postural instability and/or progressive gait
freezing (in the context of parkinsonism) were key clini-
cal features that enabled the differentiation of EOPSP
from PD.
FIG. 1. Initial (A) and final/current (B) clinical profiles of EOPSP, LOPSP, and PD. Radar charts comparing the percentage (%) of EOPSP, LOPSP, and
PD cases with Movement Disorder Society PSP diagnostic criteria clinical features in early (A) and late (B) stages of disease. EOPSP, early-onset PSP;
LOPSP, late-onset PSP; PD, Parkinson’s disease; PSP, progressive supranuclear palsy.
TABLE 3. Genetic profile of study cohort
Feature EOPSP LOPSP PD
No. of subjects 24 288 1566
MAPT H1/H1
frequency, %
92 90 67
APOE ε4 allele frequency, % 18 10 13
TRIM11 rs564309 MAF, % 21 11 15
PSP GRS z-score, mean (SE) 0.59a,b (0.13) 0.48a,b (0.05) −0.08 (0.03)
Group comparisons of PSP GRS z-scores made using Kruskal-Wallis analy-
sis of variance.
aP < 0.05 vs. PD.
bNo significant intra-group difference between Queen Square Brain Bank
and PROSPECT-UK cases.
EOPSP, early-onset PSP; LOPSP, late-onset PSP; PD, Parkinson’s disease;
MAPT, microtubule-associated protein tau; APOE, apolipoprotein E; TRIM11,
tripartite motif-containing protein 11; MAF, minor allele frequency; PSP, pro-
gressive supranuclear palsy; GRS, genetic risk score; SE, standard error.
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The final clinical profile of EOPSP closely resembled
that of LOPSP and mirrored previous studies which
have shown that initial non-RS phenotypes come to
resemble RS in the latter stages of disease.26 As we
move into a new era of potential anti-tau therapies,27
early and accurate distinction between PSP and PD will
become increasingly important. Therefore, we explored
the value of a PSP GRS and found that, at the group
level, EOPSP and LOPSP z-scores were significantly
higher in comparison with PD.
In the absence of an identified genetic mutation, the
biological drivers of early-onset presentations of neuro-
degenerative diseases such as PSP are likely to be multi-
factorial. We explored the potential aetiological roles of
encephalitis and head injury and found no significant
differences in rates between EOPSP and LOPSP.
Our findings of a longer disease duration in deceased
EOPSP cases in comparison with LOPSP is consistent
with a previous clinico-pathological study that com-
pared early-onset and late-onset PD subjects.28 One
potential explanation for this is the fact that our EOPSP
group mostly consisted of cases with PSP-P and PSP-
PGF phenotypes, which have been associated with
slower rates of disease progression.6,7,26 However,
another possibility, outside the scope of this study, is
the likelihood of lower rates of co-pathologies in
EOPSP cases, with a similar study demonstrating an
increased age at death in neurodegenerative diseases
with minimal co-pathology.29
One of the major strengths of our study was the in-
depth clinical data that was available to us from both the
QSBB case notes and serial clinical assessments of patients
in the PROSPECT-UK and Tracking Parkinson’s studies.
Within the EOPSP and LOPSP groups, the similarity
in clinico-genetic profiles between the QSBB and
PROSPECT-UK cases suggest that our findings are robust
and that the diagnostic accuracy of our PROSPECT-UK
EOPSP and LOPSP cases is high. Similar to previous
early-onset studies of movement disorders,22,23 we used
an arbitrary age at onset cut-off point to define EOPSP.
However, in our study we have gone further by investigat-
ing the impact of changing the EOPSP age at onset cut-off
point. This approach was particularly useful as it further
justified our initial approach of using an age at onset cut-
off point of ≤55 years of age to define EOPSP. When com-
pared with the other cut-off points studied, a cut-off point
of ≤55 years of age highlighted the greatest difference in
clinical phenotype and PSP GRS z-scores between the
EOPSP and LOPSP groups.
The main limitation of this study was the relatively
small number of EOPSP cases that were available for
analysis. In addition, our genetic mutation rates in EOPSP
are based on pathogenic mutations that are directly gen-
otyped on the Illumina NeuroChip, and targeted NPC1
and NPC2 sequencing was limited to cases that had bio-
chemical evidence of Niemann-Pick type C disease. A
more accurate estimation of pathogenic genetic mutation
rates will be achieved by carrying out whole-genome
sequencing of our cases. We also acknowledge that the
absence of pathological confirmation in our large PD
cohort may lead to the inclusion of non-PD patients.
However, this is likely to be applicable to a very small
number of patients as previous studies have shown that
the PPV of a clinical diagnosis of PD going on to have
pathological confirmation of PD is as high as 98.6%.25
In conclusion, EOPSP was defined as cases with a clinical
diagnosis of PSP and a motor symptom onset ≤55 years of
age. Genetic testing for familial MAPT mutations and PSP
mimics is recommended in this patient group. The diagnos-
tic accuracy of EOPSP is lower than that of LOPSP in the
early stages of disease, and this coincides with the initial
clinical profile of EOPSP being similar to PD. At the group
level, a PSP GRS was able to differentiate EOPSP from PD,
and this may be helpful in future diagnostic algorithms.
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